- Home
- RC vs PHAR Comparison
RC vs PHAR Comparison
Compare RC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- PHAR
- Stock Information
- Founded
- RC 2007
- PHAR 1988
- Country
- RC United States
- PHAR Netherlands
- Employees
- RC N/A
- PHAR N/A
- Industry
- RC Real Estate Investment Trusts
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- PHAR Health Care
- Exchange
- RC Nasdaq
- PHAR Nasdaq
- Market Cap
- RC 755.3M
- PHAR 798.2M
- IPO Year
- RC N/A
- PHAR N/A
- Fundamental
- Price
- RC $3.72
- PHAR $12.66
- Analyst Decision
- RC Hold
- PHAR Strong Buy
- Analyst Count
- RC 6
- PHAR 3
- Target Price
- RC $6.54
- PHAR $30.00
- AVG Volume (30 Days)
- RC 1.9M
- PHAR 12.6K
- Earning Date
- RC 08-07-2025
- PHAR 07-31-2025
- Dividend Yield
- RC 13.48%
- PHAR N/A
- EPS Growth
- RC N/A
- PHAR N/A
- EPS
- RC N/A
- PHAR N/A
- Revenue
- RC N/A
- PHAR $339,836,000.00
- Revenue This Year
- RC N/A
- PHAR $12.88
- Revenue Next Year
- RC $50.48
- PHAR $8.54
- P/E Ratio
- RC N/A
- PHAR N/A
- Revenue Growth
- RC N/A
- PHAR 22.44
- 52 Week Low
- RC $3.71
- PHAR $6.73
- 52 Week High
- RC $8.64
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- RC 32.26
- PHAR 60.95
- Support Level
- RC $3.80
- PHAR $12.13
- Resistance Level
- RC $3.90
- PHAR $12.76
- Average True Range (ATR)
- RC 0.13
- PHAR 0.92
- MACD
- RC -0.02
- PHAR 0.06
- Stochastic Oscillator
- RC 2.63
- PHAR 27.30
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.